In a move to further expand a comprehensive cardiovascular portfolio, Medtronic, Inc. announced today the completion of its acquisition of CoreValve Inc. CoreValve develops percutaneous, catheter-based transfemoral aortic valve replacement products. Medtronic also recently acquired Ventor Technologies, Ltd., a developer of percutaneous, catheter-based transapical aortic valve replacement products.
“These acquisitions position us as a leader in one of the most exciting new markets in medical devices. We expect a significant number of people with aortic stenosis to benefit from these break-through technologies,” said Bill Hawkins, chairman and CEO of Medtronic. “We have the scale and expertise to accelerate the use of these life-saving technologies.”
Medtronic offers an unmatched portfolio of medical devices for the treatment of cardiovascular diseases including coronary and peripheral artery disease, aortic disease, atrial fibrillation and heart valve disease. Drawing on its experience, Medtronic will continue to work toward providing patients with access to these innovative, percutaneous heart valves.